Polyzos S.A. Kountouras J. Anastasilakis A.D. Geladari E.V. Mantzoros C.S.

Irisin in patients with nonalcoholic fatty liver disease.

Metabolism. 2014; 63: 207-217Hu J. Ke Y. Wu F. Liu S. Ji C. Zhu X. et al.

Circulating Irisin levels in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Gastroenterol Res Pract. 2020; 2020: 8818191Zhang H.J. Zhang X.F. Ma Z.M. Pan L.L. Chen Z. Han H.W. et al.

Irisin is inversely associated with intrahepatic triglyceride contents in obese adults.

J Hepatol. 2013; 59: 557-562Shanaki M. Moradi N. Emamgholipour S. Fadaei R. Poustchi H.

Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes.

Diabetes Metab Syndr. 2017; 11: S467-S472Metwally M. Bayoumi A. Romero-Gomez M. Thabet K. John M. Adams L.A. et al.

A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.

J Hepatol. 2019; 70: 494-500Canivet C.M. Bonnafous S. Rousseau D. Leclere P.S. Lacas-Gervais S. Patouraux S. et al.

Hepatic FNDC5 is a potential local protective factor against non-alcoholic fatty liver.

Biochim Biophys Acta Mol Basis Dis. 1866; 2020: 165705Polyzos S.A. Kountouras J. Shields K. Mantzoros C.S.

Irisin: a renaissance in metabolism?.

Metabolism. 2013; 62: 1037-1044Boström P. Wu J. Jedrychowski M.P. Korde A. Ye L. Lo J.C. et al.

A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.

Nature. 2012; 481: 463-468Polyzos S.A. Mantzoros C.S.

An update on the validity of irisin assays and the link between irisin and hepatic metabolism.

Metabolism. 2015; 64: 937-942Polyzos S.A. Mathew H. Mantzoros C.S.

Irisin: a true, circulating hormone.

Metabolism. 2015; 64: 1611-1618Polyzos S.A. Anastasilakis A.D. Efstathiadou Z.A. Makras P. Perakakis N. Kountouras J. et al.

Irisin in metabolic diseases.

Endocrine. 2018; 59: 260-274Kechagias S. Nasr P. Blomdahl J. Ekstedt M.

Established and emerging factors affecting the progression of nonalcoholic fatty liver disease.

Metabolism. 2020; 111S: 154183Mantovani A. Scorletti E. Mosca A. Alisi A. Byrne C.D. Targher G.

Complications, morbidity and mortality of nonalcoholic fatty liver disease.

Metabolism. 2020; 111S: 154170Long M.T. Gandhi S. Loomba R.

Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.

Metabolism. 2020; 111S: 154259Miele L. Zocco M.A. Pizzolante F. De Matthaeis N. Ainora M.E. Liguori A. et al.

Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease.

Metabolism. 2020; 112: 154355Polyzos S.A. Mantzoros C.S.

Nonalcoholic fatty future disease.

Metabolism. 2016; 65: 1007-1016Boutari C. Polyzos S.A. Mantzoros C.S.

Addressing the epidemic of fatty liver disease: a call to action, a call to collaboration, a call to moving the field forward.

Metabolism. 2021; https://doi.org/10.1016/j.metabol.2021.154781:154781